Blog Layout

📖 Mid- and Long-Term Atrio-Ventricular Functional Changes in Children after Recovery from COVID-19

Sabatino et al / Journal of Clinical Medicine • 26 December 2022

❦ ‘Our findings shed new light on the cardiac impact of COVID-19 in paediatric age.

60% of children who recovered from asymptomatic or mildly symptomatic COVID-19 still exhibit mild subclinical systolic cardiac impairment after an average follow-up.’

❂

📖 (26 Dec 2022 ~ Journal of Clinical Medicine) Mid- and Long-Term Atrio-Ventricular Functional Changes in Children after Recovery from COVID-19 ➤

C-19: Archives

✾ Useful Search tags

airborne / air filtration / babies & children / body / brain / C19.Life / cancer / comment / COSHH / dementia / economy / elders / excess deaths / exercise / flu / healthcare workers (HCW) / heart / HEPA / history / HIV / hospitals / immunity / influenza / Lisa Iannattone / long covid / lungs / lymphopenia / mitochondria / muscles / musculoskeletal / NHS / NHS estates / Noor Bari / nosocomial / PEM / parkinson’s / propaganda / reinfections / reproduction and pregnancy / resources / respirators / respiratory / risk / SARS(-CoV-1) / schools / Semmelweis / solutions / transmission / UKHSA / universities / UVC / vaccines / variants / WHO / young adults / zoonosis

All Archives

✾ On SARS-CoV-2 (COVID-19), brain damage, neurological damage, and dementia

by C19.Life... et al • 21 November 2025

‘Although COVID-19 was originally considered a respiratory illness, it is now well established that SARS-CoV-2 infection can have far-reaching impacts on the nervous system. Common neurological symptoms in Long COVID [PASC] include new-onset cognitive difficulties, dysautonomia, fatigue, and peripheral neuropathy.’ from ‘Neuroimmune pathophysiology of long COVID’ by Moen et al / Psychiatry and Clinical Neurosciences (2025).

📖 Neurological and neurodevelopmental effects of Covid and MIS-C on children

by Byrne et al ~ Nature Pediatric Research / Bioengineer • 11 November 2025

‘The pediatric population, once thought to be relatively spared from severe outcomes, has presented with significant neurological manifestations that raise concerns about the short- and long-term effects of SARS-CoV-2 on the developing nervous system.’

Knock-knock... It’s mild!

by C19.Life • 5 November 2025

“How mild can a cigarette be?”

A WHO’s Who of VOCs, VOIs and VUMs: Alphabet Stew and Numeric Ragout for Dummies

by C19.Life • 1 November 2025

“We’re going to need a bigger Greek alphabet.”

'The Approved List of biological agents'. Advisory Committee on Dangerous Pathogens / UKHSA.

On Biosafety Levels, Hazard Groups, SARS-CoV-2, the UKHSA, Notifiable Organisms and Notifiable Diseases

by United Kingdom Health Security Agency (UKHSA) / Health & Safety Executive (HSE) / Control of Substances Hazardous to Health Regulations (COSHH) / C19.Life • 23 October 2025

The Health and Safety Executive (HSE) has designated SARS-CoV-2, the virus that causes COVID-19, a Hazard Group 3 (HG3) pathogen that can cause severe human disease. The United Kingdom’s Health Security Agency (UKHSA) classifies SARS-CoV-2 as a notifiable organism, and COVID-19 as a notifiable disease (2025).

📖 Guidance for Healthcare Employers and Workers on the use of Fluid Resistant Surgical Masks (FRSM) and respirators (FFP3 etc) to comply with the requirements of COSHH (2002) (England) (Updated 2025)

by The British Occupational Hygiene Society ~ COSHH and Healthcare Respiratory Protection • 20 October 2025

‘FRSMs [Surgical Masks] have never been considered either adequate or suitable equipment for protection against inhalable or respirable risks under COSHH.’

☰ 14 studies & articles on... SARS-CoV-2 (COVID-19) reinfections, cumulative damage, and increased risk of all-cause mortality

by C19.Life... et al • 29 September 2025

‘The arrival of the Omicron variant marked a major shift, introducing numerous extra mutations in the spike gene compared with earlier variants. Before Omicron, natural infection provided strong and durable protection against reinfection, with minimal waning over time. However, during the Omicron era, protection was robust only for those recently infected, declining rapidly over time and diminishing within a year.’

Show More Articles

❦ postscript

You are free to disagree with anything you read here, provided that you have an authentic, evidence-based argument for it.

❦ All content on this website is for informational and educational purposes only.

Create your business website with

Website Builder.

Share by: